Navigation Links
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
Date:6/2/2009

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Administration for L-CsA, delivered via an Investigational eFlow Nebulizer System, for the prevention and treatment of bronchiolitis obliterans, a devastating, incurable disease of the small airways affecting approximately 60,000 patients worldwide.

"PARI's encouraging results show that it is feasible and well tolerated to deposit relevant amounts of L-CsA into transplanted lungs. This has the potential to prevent and treat bronchiolitis obliterans in a more efficient way compared to current oral standard treatment. Inhaled L-CsA has a favorable drug distribution to the target sites in the lung, which should lead to lower side effects than associated with systemic cyclosporine exposure," stated Prof. Jurgen Behr, head of the Division of Respiratory Disease at the Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany.

"The long-term survival rate for lung transplant patients could be greatly improved through an effective inhaled liposomal cyclosporine therapy. Using our proprietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimized for administration via an Investigational eFlow Nebulizer System without destroying the liposome," stated Dr. Manfred Keller, executive vice president and chief scientific officer of PARI Pharma GmbH. "We had a very encouraging pre-IND meeting with the FDA, and their recent Orphan Drug Designation for L-CsA, which follows a similar designation in Europe, encourages us to move forward to solve this unmet medical need."

PARI Pharma's Phase Ib clinical trial for L-CsA studied 12 lung transplant recipients, where five patients had double lung transplants and seven patients had single lung transplants. Patients were given a single dose application of 10mg or 20mg of liposomal L-CsA, which was well tolerated. Deposition data showed a peripheral lung deposition of 2mg for a nominal, 10mg dose that was nebulized in less than ten minutes. Once daily administration of a nominal dose of 10mg L-CsA with an Investigational eFlow Nebulizer System would give approximately 14 mg L-CsA/week. Mean values for C(max) and AUC(0-inf) were up to 20ng/mL and 110 h ng/mL, respectively. These results are significantly lower compared to oral therapy. In comparison, oral CsA (Neoral(R)) therapy in lung transplant patients leads to highly variable C(max) and AUC(0-12h) values of approximately 1,800ng/mL and 8,000 h ng/mL, respectively when given twice daily in a dose of up to 250mg [Knoop 2003]. L-CsA's favorable and significantly lower pharmacokinetic values were obtained for both dose strengths tested. Phase Ib study results for L-CsA are published in the June 2009 volume of the Journal of Aerosol Medicine and Pulmonary Drug Delivery [Behr et al., Vol. 22, No. 2, p.121-129].

About PARI Pharma's Inhaled L-CsA Formulation

PARI Pharma's L-CsA is a low-dose, inhaled, liposomal cyclosporine A formulation that aims to improve the pharmacological profile, the highly variable bioavailability, and the severe side effects of oral CsA. (Severe side effects of oral CsA include kidney and brain damage, cancer, and vulnerability to infections.) L-CsA is an investigational, proprietary, liposomal formulation of 10mg CsA/2.5mL for inhalation delivery via a customized Investigational eFlow Nebulizer System. The L-CsA formulation is based on an artificial lung surfactant carrier. It is free of any irritating organic solvents and consists of unilamellar liposomes of about 100nm. The unilamellar liposomes are obtained via a high-pressure homogenization process using standard pharmaceutical equipment followed by sterile filtration and lyophilization. The product has been scaled up to production batch sizes, and preliminary stability data indicate that a shelf life of more than 2 years at room temperature is feasible.

About the Investigational eFlow Nebulizer System and eFlow Technology

The Investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. The Investigational eFlow Nebulizer System and eFlow Technology are proprietary to PARI Pharma.

About Bronchiolitis Obliterans

According to the International Society of Heart and Lung Transplantation Registry, development of bronchiolitis obliterans is the single most important risk factor for five-year mortality among lung transplant patients. Bronchiolitis obliterans is an incurable small airways disease, which manifests as chronic allograft rejection and results in airflow obstruction. The disease is also a factor in other lung diseases such as collagen vascular diseases, inhalation of toxic fumes, and respiratory tract infections. Bronchiolitis obliterans affects approximately 60,000 patients worldwide, and once it develops, most patients die of respiratory failure within 5 years.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices, drug formulations, and therapies for upper and lower respiratory indications. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized and customized per investigational drug product and are currently in clinical trials for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications.

PARI Pharma provides comprehensive inhalation drug development, including nebulizer formulation development and optimization, analytics, aerosol characterization, clinical protocol development, and regulatory guidance, all in compliance with CMC/GCP guidelines. PARI Pharma has several clinical development programs ongoing, either partnered or on its own. Proprietary programs in different development stages will be offered for licensing partnerships.

Online at www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
11. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... The South Korean Proton ... market size in 2016. The Untapped Proton Therapy Market for ... in 2016. Proton Therapy plays an important role in ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... Calif. , March 29, 2017 ... for patients as the highest standard in quality ... Krypton Vision introduces its objective Wavefront-driven refraction technologies ... subjective approach. This enables an unprecedented level of ... - exceptional vision relegated to Topgun Navy fighter ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... , ... An inventor and manicurist from Greet, S.C., wants to offer people a new way ... maintain clean and healthy feet, so I know the importance of proper foot care," he ... designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate ...
(Date:3/30/2017)... ... March 30, 2017 , ... This ... to President Trump expressing their support for an independent Vaccine Safety Commission. Five ... and one medical journalist, will hold a press conference at 9:00 AM ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
Breaking Medicine News(10 mins):